

2 **Endobronchial valve lung volume reduction and small airways function**

3 J L Garner^{1,3}, M F Biddiscombe^{1,3}, S Meah¹, A Lewis^{1,4}, S C Buttery^{1,3},

4 N S Hopkinson^{1,3}, S V Kemp^{1,3}, O S Usmani^{1,3†#}, P L Shah^{1-3#}, S Verbanck^{5#}

5 # contributed equally

6
7 ¹Royal Brompton Hospital, London, UK.

8 ²Chelsea & Westminster Hospital, London, UK.

9 ³National Heart & Lung Institute, Imperial College London, London, UK.

10 ⁴Brunel University London, Uxbridge, UK

11 ⁵University Hospital UZ Brussel, Brussels, Belgium.

12
13 **Correspondence:** †Dr Omar Usmani, Respiratory Department, Imperial College
14 London, Dovehouse Street, London SW3 6LY. email: o.usmani@imperial.ac.uk

15
16 **Contributors:** JLG, OSU, PLS, SV designed the analysis, wrote the first draft of the
17 manuscript, and made revisions after feedback from co-authors. All the authors meet
18 the definition of an author as stated by the International Committee of Medical Journal
19 Editors, and all have seen and approved the final manuscript.

20
21 **Short title:** Reduced air flow limitation post-endobronchial valves.

22 **Keywords:** Emphysema, endobronchial valve, hyperinflation, oscillometry, multiple
23 breath nitrogen washout, peripheral lung physiology.

24 **Word count:** 1030

25 **Funding:** None

26 **At a Glance Commentary**

27 ***Scientific knowledge on the subject:***

28 Lung volume reduction (LVR) has been shown to improve lung function, exercise
29 capacity, quality of life, and survival in selected individuals with severe emphysema
30 and hyperinflation. However, the impact of LVR on the function of the small airways,
31 the principal site of airflow obstruction in COPD, is largely unknown. Sensitive
32 physiological techniques of oscillometry and ventilation distribution can provide
33 additional insight into mechanisms of benefit from these procedures.

34

35 ***What this study adds to the field:***

36 LVR with endobronchial valves led to improvements in oscillometry and multiple
37 breath nitrogen washout measures reflecting reductions of airflow limitation and
38 ventilation inhomogeneity. These data provide mechanistic support for the beneficial
39 impact of bronchoscopic LVR on peripheral lung function.

40

41

42

43

44

45

46

47

48

49 The small airways (those <2mm internal diameter) offer little resistance to airflow in
50 health, however the response to repetitive and continual insult by inhaled noxious
51 particles causes them to become the principal site of impediment to airflow in chronic
52 obstructive pulmonary disease (COPD). As disease progresses, several
53 pathophysiological mechanisms collectively lead to emphysema and lung
54 hyperinflation, recognized as significant contributors to the patient's perception of
55 breathlessness and activity limitation that predicts not only the risk and severity of
56 exacerbations, but also all-cause mortality. These observations have stimulated
57 interest in lung volume reduction (LVR) techniques, lung volume reduction surgery
58 (LVRS) and more recently, placement of endobronchial valves (EBVs) which limit air
59 entry but permit unimpeded expulsion of air and mucus, to deflate the lung in an
60 attempt to restore respiratory mechanics. Accruing evidence supports the concept of
61 LVR to improve lung function, exercise capacity, quality of life, and survival. Volume
62 reduction is the key driver of the benefit(1).

63 Although the small airways are the principal site of disease pathogenesis, the effects
64 of LVR on small airways function are largely unknown. Bilateral LVRS undertaken in
65 29 patients with severe emphysema has demonstrated more efficient small airways
66 lung ventilation with scintigraphic imaging of regional lung ¹³³Xe gas washout(2).
67 Oscillometry in 23 patients whose heterogeneous emphysema or emphysematous
68 bullae had been treated with histoacryl gel, an experimental 'biological' LVR not
69 clinically approved for routine practice, showed a decreased R_{5Hz}, with unaltered
70 X_{5Hz}(3).

71 Here, we study the impact on lung mechanics of EBVs. We hypothesized that EBVs
72 implanted in the proximal bronchi of the most severely diseased lung lobe(s), would

73 lead to functional improvements in the peripheral lung. Small airways function was
74 assessed using oscillometry and ventilation distribution tests.

75

76 **Methods**

77 In a prospective observational study (ethics reference 14/SC/0193), COPD patients
78 with severe emphysema and without collateral ventilation, underwent EBV placement
79 (Zephyr, PulmonX, USA). During stable disease state before and three months after
80 the procedure, patients underwent clinical phenotyping: symptom scores (mMRC and
81 SGRQ), functional exercise capacity (six-minute walk distance), radiological
82 assessment, lung function testing. Post-bronchodilation (400mcg albuterol), routine
83 body plethysmography was followed by impulse oscillometry (IOS; Cardinal Health,
84 Hoechberg, Germany) and multiple-breath nitrogen washout (MBN₂W) testing (PK-
85 Morgan, Rainham, UK), as described previously(4). Wilcoxon signed-rank tests were
86 performed using GraphPad Prism (v8, San Diego, CA), with significance at p<0.05.

87

88 **Results**

89 Twelve COPD patients (five female) participated with a baseline median mMRC score
90 2.5 and SGRQ-total score 50.9 and features of very severe airflow obstruction (FEV₁
91 28% predicted), hyperinflation (RV 225% predicted), and radiological signs of
92 emphysema (**Table 1**). Three months post procedure, with a radiologically verified
93 median volume reduction of 730mls, significant gains were observed in spirometry,
94 static lung volumes (RV and RV/TLC), exercise capacity, and SGRQ-activity score
95 (**Table 1**). Distinct improvements were obtained for IOS indices of reactance ($X_{5\text{Hz}}$;
96 $p=0.013$ and $X_{\text{in}5\text{Hz}}-X_{\text{ex}5\text{Hz}}$; $p=0.010$)(5,6), and for MBN₂W indices of lung clearance
97 index (LCI; $p=0.006$) and alveolar mixing efficiency (AME; $p=0.001$)(7) (**Table 1**).

98 During follow-up, four patients developed pulmonary infections: two pneumonias, two
99 COPD exacerbations. No pneumothoraces were recorded.

100

101 **Discussion**

102 We have shown that LVR utilising EBVs, with resulting CT-measured and
103 plethysmography-derived lung volume reductions that were clinically meaningful, led
104 to significant changes in the oscillometry index of $X_{in5Hz}-X_{ex5Hz}$ (difference between
105 inspiratory and expiratory reactance), a surrogate measure of expiratory flow limitation
106 (EFL) in COPD(5). The consistency of our $X_{in5Hz}-X_{ex5Hz}$ data corroborates previous
107 reports of how pulmonary mechanics of the peripheral airways are best assessed in
108 obstructive airways disease(6). Reactance normally reflects the elastic and inertial
109 properties of the respiratory system but in the presence of EFL, the oscillatory signal
110 is unable to pass through the choke points, reducing the apparent compliance during
111 expiration, and this is aggravated by worsening hyperinflation. Mechanistically, we
112 propose b-LVR decreases EFL of the small airways as observed by a reduction in
113 reactance at 5Hz. We also observed improvement in MBN₂W indices LCI and AME
114 reflecting a more even ventilation distribution throughout the lung(7), consistent with
115 findings from a scintigraphic imaging study showing more efficient gas mixing(2). In
116 patients where the acinar component of ventilation (S_{acin}) is the predominant driver
117 of abnormal ventilation distribution, AME may suffice to monitor the impact of EBVs(7).
118 Mechanistically, improved ventilatory inhomogeneity may explain the improved
119 oxygen kinetics observed following LVR(8).

120 Emphysema with hyperinflation is a hallmark of severe COPD, with substantial loss of
121 terminal bronchioles, destruction of the elastic scaffold maintaining patency of airways
122 and facilitating passive recoil, and compromising tissue with functional potential(9).

123 Lung volume reduction aims to disencumber the mechanically disadvantaged
124 ventilatory pump, deflating redundant parenchyma, reviving less diseased tissue, and
125 re-tensioning the remaining airway network(9). This is conceptually attractive to
126 explain the improvement of the physiological small airway function indices observed
127 here together with the decrease in RV. Not unexpectedly, there was a significant
128 residual impairment in small airways function persisting after valve implantation, as
129 illustrated by S_{acin} (**Table 1**). Post procedure, S_{acin} was compatible with values
130 previously observed in COPD(10), and which could be attributed to the extensive loss
131 of terminal bronchioles in addition to emphysema.

132 When assessing small airways function with physiological tests in interventional
133 studies, it is important to consider the volumetric effect. That is, purely on volumetric
134 grounds, a reduction in ventilated FRC would normally increase R_{5Hz} and decrease
135 X_{5Hz} (i.e., make X_{5Hz} more negative). If we consider small airways function by focusing
136 on R_{in5Hz} and X_{in5Hz} , irrespective of EFL, neither of these indices changed post-EBVs
137 (**Table 1**). As mentioned above, this could represent a counter-balancing effect of the
138 ventilated FRC decrease and signal a small improvement in small airway mechanics
139 over and above the purely volumetric effect of EBV lung volume reduction. LCI and
140 AME are inherently less sensitive to FRC and represent physiological evidence of
141 improved ventilation distribution akin to that observed by radioisotopes in similar
142 patients(7). Importantly, adverse events did not appear to impact on three-month
143 outcomes. Our study was uncontrolled and unblinded and did not allow identification
144 of individual lobar expansion, which would only have been possible if additional CT
145 images per patient had been obtained.

146 In conclusion, our data provide mechanistic support for the benefits of LVR with
147 proximal placement of EBVs, in improving small airways function in patients with
148 severe emphysema and hyperinflation.

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170 **DECLARATION OF INTERESTS**

171 **JLG** has no disclosures. **MFB** has no disclosures. **SM** has no disclosures. **AL** has no
172 disclosures. **SB** has no disclosures. **NSH** has no disclosures. **SVK** reports personal
173 fees from PulmonX Inc, personal fees from Boston Scientific, outside the submitted
174 work. **OSU** reports grants and personal fees from Astra Zeneca, grants and personal
175 fees from Boehringer Ingelheim, grants and personal fees from Chiesi, grants and
176 personal fees from GlaxoSmithKline, personal fees from NAPP, personal fees from
177 Mundipharma, personal fees from Sandoz, personal fees from Takeda, grants from
178 Edmond pharma, personal fees from Cipla, personal fees from Covis, personal fees
179 from Novartis, personal fees from Mereobiopharma, personal fees from Orion,
180 personal fees from Menarini, outside the submitted work. **PLS** reports personal fees
181 for lectures Nuvairia & sponsorship to Imperial College for a bronchoscopy course by
182 from ERBE, Cook medical, Medtronic, Boston Scientific, Broncus, Nuvaria, Pulmonx,
183 Olympus, & PneumRX/BTG, outside the submitted work. He has been an investigator
184 on clinical trials with endobronchial valves. **SV** has no disclosures.

185

186 **REFERENCES**

- 187 1. van Geffen WH, Slebos DJ, Herth FJ, Kemp SV, Weder W, Shah PL. Surgical and
188 endoscopic interventions that reduce lung volume for emphysema: a systemic review
189 and meta-analysis. *The Lancet Respiratory Medicine* 2019;7(4):313-24.
- 190 2. Travaline JM, Maurer AH, Charkes ND, Urbain JL, Furukawa S, Criner GJ.
191 Quantitation of regional ventilation during the washout phase of lung scintigraphy:
192 measurement in patients with severe COPD before and after bilateral lung volume
193 reduction surgery. *Chest* 2000;118(3):721-7.
- 194 3. Khattab A, Abd Elfattah N, Farghaly A, Hassan A. Assessment of lung functions
195 using impulse oscillometry before and after bronchoscopic lung volume reduction with
196 histoacryl gel. *Egyptian Journal of Bronchology* 2019;13(1):43-8.4. Verbanck S,
197 Thompson BR, Schuermans D, Kalsi H, Biddiscombe M, Stuart-Andrews C, et al.
198 Ventilation heterogeneity in the acinar and conductive zones of the normal ageing
199 lung. *Thorax* 2012;67:789-95.
- 200 5. Dellacà RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of
201 bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. *The*
202 *European Respiratory Journal* 2009;33(6):1329-37.
- 203 6. Paredi P, Goldman M, Alamen A, Ausin P, Usmani OS, Pride NB, Barnes PJ.
204 Comparison of inspiratory and expiratory resistance and reactance in patients with
205 asthma and chronic obstructive pulmonary disease. *Thorax* 2010;65(3):263-7.
- 206 7. Verbanck SAB, Polfliet M, Schuermans D, Ilsen B, de Mey J, Vanderhelst E, et al.
207 Ventilation heterogeneity in smokers: role of unequal lung expansion and peripheral
208 lung structure. *J Appl Physiol (1985)* 2020;19(3):583-590.

- 209 8. Faisal A, Zoumot Z, Shah PL, Neder JA, Polkey MI, Hopkinson NS. Effective
210 Bronchoscopic Lung Volume Reduction Accelerates Exercise Oxygen Uptake Kinetics
211 in Emphysema. *Chest*. 2016;149(2):435-446.
- 212 9. Garner JL, Shah PL. Lung Volume Reduction in Pulmonary Emphysema. *Semin*
213 *Respir Crit Care Med* 2020 May 20. doi: 10.1055/s-0040-1702192.
- 214 10. Verbanck S, King GG, Paiva M, Schuermans D, Vanderhelst E. The Functional
215 Correlate of the Loss of Terminal Bronchioles in Chronic Obstructive Pulmonary
216 Disease. *Am J Respir Crit Care Med* 2018;197(12):1633-5.